{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:24:39Z","timestamp":1772601879712,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Neuroendocrine neoplasms (NENs) are neoplastic tumors developing in every part of the body, mainly in the gastrointestinal tract and pancreas. Their treatment involves the surgical removal of the tumor and its metastasis, long-acting somatostatin analogs, chemotherapy, targeted therapy, and radioligand therapy (RLT). Materials and Methods: A total of 127 patients with progressive neuroendocrine neoplasms underwent RLT\u20144 courses, administered every 10 weeks\u2014with the use of 7.4 GBq [177Lu]Lu-DOTA-TATE or tandem therapy with 1.85 GBq [177Lu]Lu-DOTA-TATE and 1.85 GBq [90Y]Y-DOTA-TATE. Assessment of short- and long-term complications, as well as the calculation of progression-free survival (PFS) and overall survival (OS) were performed. Results: RLT caused a statistically but not clinically significant decrease in blood morphology parameters during both short- and long-term observations. Glomerular filtration rate (GFR) significantly decreased only in a long-term observation after RLT; however, it was clinically acceptable. Computed predictions of progression-free survival (PFS) and overall survival (OS) indicated that five years post-RLT, there is a 74% chance of patients surviving, with only a 58.5% likelihood of disease progression. Conclusions: Computed predictions of PFS and OS confirmed treatment efficiency and good patient survival. RLT should be considered a safe and reliable line of treatment for patients with progressive NENs as it causes only a low number of low-grade adverse events.<\/jats:p>","DOI":"10.3390\/cancers16203509","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T08:56:32Z","timestamp":1729155392000},"page":"3509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-2577","authenticated-orcid":false,"given":"Adam Daniel","family":"Durma","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Saracyn","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-264X","authenticated-orcid":false,"given":"Maciej","family":"Ko\u0142odziej","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-5415","authenticated-orcid":false,"given":"Katarzyna","family":"J\u00f3\u017awik-Plebanek","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-1537","authenticated-orcid":false,"given":"Dorota","family":"Brodowska-Kania","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Dmochowska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna","family":"Mr\u00f3z","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-1722","authenticated-orcid":false,"given":"Beata","family":"Kos-Kud\u0142a","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-0634","authenticated-orcid":false,"given":"Grzegorz","family":"Kami\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine\u2014National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"xv","DOI":"10.1016\/j.soc.2020.01.001","article-title":"Neuroendocrine Tumors","volume":"29","author":"Howe","year":"2020","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.gtc.2022.06.002","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"51","author":"Fernandes","year":"2022","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.path.2019.10.002","article-title":"Pulmonary Neuroendocrine Tumors","volume":"13","author":"Borczuk","year":"2020","journal-title":"Surg. Pathol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jtho.2020.06.021","article-title":"Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines","volume":"15","author":"Singh","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","first-page":"375","article-title":"Primary well differentiated neuroendocrine tumor of ovary collides with Mucinous borderline tumor in a postmenopausal female: A report of case and review of literature","volume":"109","author":"Shahid","year":"2017","journal-title":"Pathologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/0377-4929.200020","article-title":"Well differentiated neuroendocrine tumor of the kidney: Report of a rare case with review of literature","volume":"60","author":"Mardi","year":"2017","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12659\/AJCR.894463","article-title":"Primary neuroendocrine tumor (carcinoid tumor) of the testis: A case report with review of literature","volume":"16","author":"Lubana","year":"2015","journal-title":"Am. J. Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cpet.2022.10.002","article-title":"Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management","volume":"18","author":"Ramesh","year":"2023","journal-title":"PET Clin."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yao, H., Hu, G., Jiang, C., Fan, M., Yuan, L., Shi, H., and Lin, R. (2023). Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1241724"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12020-023-03649-4","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: A review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database","volume":"84","author":"Panzuto","year":"2024","journal-title":"Endocrine"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Masui, T., Ito, T., Komoto, I., Uemoto, S., and JNETS Project Study Group (2020). Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: A population-based study. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07581-y"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rossi, R.E., and Massironi, S. (2022). The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133794"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-024-00508-y","article-title":"Gastric neuroendocrine neoplasms","volume":"10","author":"Lamberti","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5603\/EP.a2022.0049","article-title":"Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zalece\u0144 og\u00f3lnych dotycz\u0105cych post\u0119powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych uk\u0142adu pokarmowego (rekomendowane przez Polsk\u0105 Sie\u0107 Guz\u00f3w Neuroendokrynnych)]","volume":"73","author":"Foltyn","year":"2022","journal-title":"Endokrynol. Pol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","article-title":"Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review","volume":"21","author":"Broder","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2019.1559294","article-title":"The safety of lanreotide for neuroendocrine tumor","volume":"18","author":"Godara","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides, 1.8.F.-D.O.P.A","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lugat, A., Frampas, \u00c9., Touchefeu, Y., Miralli\u00e9, \u00c9., Bras, M.L., Senellart, H., Rauscher, A., Fleury, V., Campion, L., and Rohmer, V. (2023). Prospective Multicentric Assessment of 68Ga-DOTANOC PET\/CT in Grade 1-2 GEP-NET. Cancers, 15.","DOI":"10.3390\/cancers15020513"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.12998\/wjcc.v8.i17.3697","article-title":"Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix","volume":"8","author":"Saponjski","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"ref_25","first-page":"518","article-title":"Neuroendocrine tumors\u2019 patients treated with somatostatin analogue could complicate with emergency cholecystectomy","volume":"94","author":"Calomino","year":"2023","journal-title":"Ann. Ital. Chir."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms","volume":"103","author":"Sundin","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s00259-020-04690-5","article-title":"Tandem peptide receptor radionuclide therapy using 90Y\/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects\u2014Polish multicenter experience","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","first-page":"82","article-title":"Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival","volume":"40","year":"2021","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol. Engl. Ed."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Durma, A.D., Saracyn, M., Ko\u0142odziej, M., J\u00f3\u017awik-Plebanek, K., Dmochowska, B., Kapusta, W., \u017bmudzki, W., Mr\u00f3z, A., Kos-Kud\u0142a, B., and Kami\u0144ski, G. (2023). Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center. Cancers, 15.","DOI":"10.3390\/cancers15225466"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zanini, S., Renzi, S., Giovinazzo, F., and Bermano, G. (2020). mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.562505"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in the treatment of neuroendocrine tumors: Efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e12784","DOI":"10.1097\/MD.0000000000012784","article-title":"Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis","volume":"97","author":"Lu","year":"2018","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13227","DOI":"10.1111\/jne.13227","article-title":"FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors","volume":"35","author":"Lacombe","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Saracyn, M., Durma, A.D., Bober, B., Ko\u0142odziej, M., Lubas, A., Kapusta, W., Niemczyk, S., and Kami\u0144ski, G. (2022). Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms. Nutrients, 15.","DOI":"10.3390\/nu15010185"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bober, B., Saracyn, M., Zar\u0119ba, K., Lubas, A., Mazurkiewicz, P., Wili\u0144ska, E., and Kami\u0144ski, G. (2022). Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms\u2014A Preliminary Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040919"},{"key":"ref_38","first-page":"73","article-title":"Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects","volume":"20","author":"Parghane","year":"2020","journal-title":"World J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e27747","DOI":"10.1002\/pbc.27747","article-title":"Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events","volume":"66","author":"Miller","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12149-017-1163-6","article-title":"Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y\/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: A 10-year study","volume":"31","author":"Kunikowska","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.34191","article-title":"Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu-octreotate peptide radionuclide therapy","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Trautwein, N.F., Schwenck, J., Jacoby, J., Reischl, G., Fiz, F., Zender, L., Dittmann, H., Hinterleitner, M., and la Foug\u00e8re, C. (2023). Long-term prognostic factors for PRRT in neuroendocrine tumors. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1169970"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/MPA.0000000000000734","article-title":"Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors","volume":"46","author":"Sharma","year":"2017","journal-title":"Pancreas"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/ERC-16-0524","article-title":"Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate","volume":"24","author":"Brabander","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00259-009-1151-8","article-title":"Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function","volume":"36","author":"Teunissen","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Urso, L., Panareo, S., Castello, A., Ambrosio, M.R., Zatelli, M.C., Caracciolo, M., Tonini, E., Valpiani, G., Boschi, A., and Uccelli, L. (2022). Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu\/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102009"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/20\/3509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:15:03Z","timestamp":1760112903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/20\/3509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":48,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16203509"],"URL":"https:\/\/doi.org\/10.3390\/cancers16203509","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}